- Home
- NGNE vs RVI Comparison
NGNE vs RVI Comparison
Compare NGNE & RVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGNE | RVI |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 849.0M |
| IPO Year | 2014 | 2026 |
Fundamental Metrics
Financial Performance| Metric | NGNE | RVI |
|---|---|---|
| Price | $34.41 | $25.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $63.57 | N/A |
| AVG Volume (30 Days) | 310.4K | ★ 331.2K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $22.21 |
| 52 Week High | $43.66 | $77.39 |
Technical Indicators
Market Signals| Indicator | NGNE | RVI |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 32.67 |
| Support Level | $18.24 | $24.39 |
| Resistance Level | $37.27 | $35.53 |
| Average True Range (ATR) | 3.04 | 1.92 |
| MACD | -0.65 | -0.05 |
| Stochastic Oscillator | 17.67 | 7.11 |
Price Performance
Historical ComparisonAbout NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About RVI Robinhood Ventures Fund I Common Shares of Beneficial Interest
Robinhood Ventures Fund I is a closed-end investment company. The investment objective, the Fund will mainly invest, under normal circumstances, in a concentrated portfolio generally consisting of ten or more private companies that, in the view, are growing companies at the frontiers of their respective sectors and industries. The Fund operates as a single segment.